Table 3.
Medical Treatment of Patients Stratified by LVEF
| Total | All Patients | LVEF < 40% | LVEF 40–49% | LVEF ≥ 50% | p value |
|---|---|---|---|---|---|
| 126 | 32 | 37 | 57 | ||
| Angiotensin converting enzyme inhibitors (ACEIs) – No (%) | 75 (59.5%) | 15(46.8%) | 19(51.3%) | 41(71.9%) | 0.0340 |
| Angiotensin AT1 receptor blockers (ARBs) – No (%) | 49 (38.8%) | 22(68.7%) | 9(24.3%) | 18(31.5%) | 0.0054 |
| Sacubitril/valsartan – No (%) | 12 (9.5%) | 8(25%) | 1 (2.7%) | 0(0) | 0.0018 |
| Beta-blockers – No (%) | 121(96%) | 30(93.7%) | 35(94.5%) | 56 (98.2%) | NS |
| Ivabradine – No (%) | 10 (7.9%) | 4 (12.5%) | 4 (10.8%) | 2(3.5%) | NS |
| Long-lasting nitrates – No (%) | 28(22.2%) | 2(6.2%) | 23(62.1%) | 3 (5.2%) | <0.0001 |
| Calcium channel blockers – No (%) | 6 (4.7%) | 3 (9.3%) | 1(2.7%) | 2(3.5%) | NS |
| Antiarrhythmics – No (%) | 39 (30.9%) | 8 (25%) | 11(29.7%) | 20(35%) | NS |
| Anti-aldosterone agents (MRAs) – No (%) | 69 (54.7%) | 30 (93%) | 28 (75%) | 11 (19%) | NS |
| Anticoagulants – No (%) | 72 (57.1%) | 20(62.5%) | 19(51.3%) | 33(57.8%) | NS |
Note: p < 0.05 was statistically significant.